Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with multiple sclerosis

By Weir Scott   Gao Yuying   Henney Herbert R.  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1637-1645

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis

By Weir Scott   Torkin Risa   Henney III Herbert R.  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1627-1636

Informa Healthcare

Access to resources Recommend Favorite

Impact of Walking Impairment in Multiple Sclerosis: Perspectives of Patients and Care Partners

By LaRocca Nicholas G.  

The Patient: Patient-Centered Outcomes Research, Vol. 4, Iss. 3, 2011-09 ,pp. : 189-201

Adis International

Access to resources Recommend Favorite

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

By Hutchinson Michael   Fox Robert J.   Havrdova Eva   Kurukulasuriya Nuwan C.   Sarda Sujata P.   Agarwal Sonalee   Siddiqui Mohd Kashif   Taneja Ankush   Deniz Baris  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 613-627

Informa Healthcare

Access to resources Recommend Favorite

Cough Efficacy Is Related to the Disability Status in Patients with Multiple Sclerosis

By  

Respiration, Vol. 76, Iss. 3, 2008-03 ,pp. : 311-316

Karger

Access to resources Recommend Favorite